MarketCap
Facebook
X
TelegramProgenity, Inc. Total Current Liabilities 2011-2026 | PROG
Annual Total Current Liabilities Progenity, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 72.7 M | 100 M | 78.1 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 100 M | 72.7 M | 83.7 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
4.59 M | $ 0.89 | -0.61 % | $ 6.54 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.57 | 1.21 % | $ 3.74 B | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
11 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
13.2 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
19.9 M | - | -0.88 % | $ 598 M | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
36.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.09 | -0.37 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
130 M | $ 23.2 | -0.96 % | $ 2.95 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.48 | 3.87 % | $ 394 M |  Britain |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.9 | -0.64 % | $ 4.77 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
20.8 M | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
16.4 M | $ 1.71 | -0.58 % | $ 114 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
81.1 M | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
53.9 M | $ 1.07 | -1.83 % | $ 13.1 M | USA |
 |
Cabaletta Bio
CABA
|
50.2 M | $ 2.8 | -3.95 % | $ 281 M | USA |